India Resurgence Fund to Acquire Ind-Swift Labs' APIs and CRAMS Business

The India Resurgence Fund, backed by Piramal Enterprises and Bain Capital, will acquire Ind-Swift Laboratories' APIs and CRAMS business for INR 1,650 crore through portfolio company Synthimed Labs. The board of Ind-Swift Labs approved the sale on September 6. Ind-Swift reported FY23 revenue of INR 1,207 crore and EBITDA of INR 256 crore.

 

Ind-Swift is a leading independent API business in India with manufacturing sites in Punjab and Jammu. It serves both regulated and unregulated markets with a combined reactor capacity of around 700 KL. The API business extends globally. Shareholder and regulatory approvals are pending for the transaction.

 

Synthimed Labs will also acquire an intermediate manufacturing facility from the promoter group. Shantanu Nalavadi, Managing Director of IndiaRF, stated, "We're committed to injecting capital for expansion and new product development to better serve our customers."

 

PwC advised Ind-Swift on this transaction.

 

Source: Media Reports

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions